NAFLD-related HCC.

Nonalcoholic fatty liver disease (NAFLD) is one of the major drivers for the rising trend in hepatocellular carcinoma (HCC). Over the past three decades, the incidence of both NAFLD and HCC have increased two- to threefold. It has been forecasted that the number of patients with NAFLD in the Unites States will reach 101 million by 2030; global increase is also foreseen. This trend will likely continue to translate into increased HCC in the Unites States and across the globe. In this chapter, we summarize the current evidence linking NAFLD, metabolic syndrome, particularly obesity and type 2 diabetes mellitus, and HCC. We describe the main molecular mechanisms connecting these metabolic perturbations and hepatocarcinogenesis.

• Publication year

  2021

• Venue

  Advances in Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/bs.acr.2020.11.001PMID 33579423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

  2020cited by this paper
• Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

  2020cited by this paper
• Obesity and cancer risk: Emerging biological mechanisms and perspectives.

  2019cited by this paper
• Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma

  2019cited by this paper
• Past, present and future perspectives in nonalcoholic fatty liver disease

  2019cited by this paper
• Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations

  2019cited by this paper
• Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

  2018cited by this paper
• Alterations of methionine metabolism in hepatocarcinogenesis: the emergent role of glycine N-methyltransferase in liver injury

  2018cited by this paper
• Mechanisms of NAFLD development and therapeutic strategies

  2018cited by this paper
• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

  2018cited by this paper
• The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity

  2018cited by this paper
• Should we undertake surveillance for HCC in patients with NAFLD?

  2018cited by this paper
• Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma

  2018cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018cited by this paper
• Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis

  2017cited by this paper
• Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.

  2017cited by this paper
• MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals

  2017cited by this paper
• Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.

  2017cited by this paper
• The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease

  2017cited by this paper
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

  2017cited by this paper
• MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis

  2017cited by this paper
• Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data

  2017cited by this paper
• Diabetes and adiposity: a heavy load for cancer.

  2017cited by this paper
• Adiposity and cancer at major anatomical sites: umbrella review of the literature

  2017cited by this paper
• Epidemiology and natural history of non-alcoholic fatty liver disease.

  2016cited by this paper
• Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease

  2016cited by this paper
• Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease‐related hepatocellular carcinoma

  2016cited by this paper
• Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.

  2016cited by this paper
• NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

  2016cited by this paper
• Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.

  2016cited by this paper
• Obesity and cancer: An update of the global impact.

  2016cited by this paper
• Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.

  2016cited by this paper
• The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus

  2016cited by this paper
• Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma

  2015cited by this paper
• Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.

  2015cited by this paper
• Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins.

  2015cited by this paper
• Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

  2015cited by this paper
• Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma

  2015cited by this paper
• Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

  2015cited by this paper
• Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009

  2015cited by this paper
• STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.

  2015cited by this paper
• TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease

  2015cited by this paper
• Immunomodulation by Gut Microbiota: Role of Toll-Like Receptor Expressed by T Cells

  2014cited by this paper
• Leptin signaling molecular actions and drug target in hepatocellular carcinoma

  2014cited by this paper
• Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.

  2014cited by this paper
• Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

  2014cited by this paper
• Genome-Wide Analysis of Copy Number Variation Identifies Candidate Gene Loci Associated with the Progression of Non-Alcoholic Fatty Liver Disease

  2014cited by this paper
• Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

  2014cited by this paper
• Hepatocyte Toll-like Receptor 4 Regulates Obesity-Induced Inflammation and Insulin Resistance

  2014cited by this paper
• Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes.

  2014cited by this paper
• Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing

  2014cited by this paper
• Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis

  2014cited by this paper
• Obesity and cancer—mechanisms underlying tumour progression and recurrence

  2014cited by this paper
• TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

  2014cited by this paper
• Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers.

  2014cited by this paper
• Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV‐ and HCV‐endemic area of Southern Taiwan

  2013cited by this paper
• Role of the Hedgehog pathway in hepatocellular carcinoma (review).

  2013cited by this paper
• Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

  2013cited by this paper
• Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

  2013cited by this paper
• PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease.

  2013cited by this paper
• Non‐alcoholic fatty liver disease contributes to hepatocarcinogenesis in non‐cirrhotic liver: A clinical and pathological study

  2013cited by this paper
• Epidemiology of hepatocellular carcinoma: consider the population.

  2013cited by this paper
• Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis

  2013cited by this paper
• Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort

  2013cited by this paper
• Resolution of fatty liver and risk of incident diabetes.

  2013cited by this paper
• Failure Rates in the Hepatocellular Carcinoma Surveillance Process

  2012cited by this paper
• Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

  2012cited by this paper
• Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

  2012cited by this paper
• Evaluation of TNF-α and IL-6 Levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects

  2012cited by this paper
• Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes

  2012cited by this paper
• Immunological functions of leptin and adiponectin.

  2012cited by this paper
• Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

  2012cited by this paper
• Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.

  2012cited by this paper
• Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease

  2012cited by this paper
• Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.

  2011cited by this paper
• Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity

  2011cited by this paper
• Prevalence, gender, ethnic variations, and prognosis of NASH

  2011cited by this paper
• Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey

  2011cited by this paper
• Mechanisms and Implications of Age-Related Changes in the Liver: Nonalcoholic Fatty Liver Disease in the Elderly

  2011cited by this paper
• The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

  2011cited by this paper
• NF-κB and STAT3 – key players in liver inflammation and cancer

  2011cited by this paper
• Coupling global methylation and gene expression profiles reveal key pathophysiological events in liver injury induced by a methyl-deficient diet.

  2011cited by this paper
• Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants.

  2011cited by this paper
• Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection

  2010cited by this paper
• The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

  2010cited by this paper
• Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis

  2010cited by this paper
• Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association.

  2010cited by this paper
• Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase

  2010cited by this paper
• Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.

  2010cited by this paper
• Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

  2010cited by this paper
• Release of Inflammatory Mediators by Human Adipose Tissue Is Enhanced in Obesity and Primarily by the Nonfat Cells: A Review

  2010cited by this paper
• Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

  2009cited by this paper
• Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

  2009cited by this paper
• Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer

  2009cited by this paper
• NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-up Study

  2009cited by this paper
• Serum IL‐6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: An analysis based on gender differences

  2009cited by this paper
• Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.

  2008cited by this paper
• A core gut microbiome in obese and lean twins

  2008cited by this paper

• Genomic Alterations and Microbiota Crosstalk in Hepatic Cancers: The Gut–Liver Axis in Tumorigenesis and Therapy

  2025cites this paper
• Programmed cell death protein 5 inhibits hepatocellular carcinoma progression by inducing pyroptosis through regulation of TGF-β/Smad2/3/Snail pathway.

  2025cites this paper
• PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer

  2024cites this paper
• A PRAGMATIC MANAGEMENT APPROACH FOR METABOLIC DYSFUNCTION ASSOCIATED STEATOSIS AND STEATOHEPATITIS.

  2024cites this paper
• Identifying the Crucial Biomarker of MASH-Related HCC

  2024cites this paper
• HEPATOCELLULAR CARCINOMA IN A LARGE COHORT OF TYPE 2 DIABETES PATIENTS.

  2023cites this paper
• Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis

  2023cites this paper
• Performance of the Enhanced Liver Fibrosis Score, Comparison with Vibration-controlled Transient Elastography Data, and Development of a Simple Algorithm to Predict Significant Liver Fibrosis in a Community-based Liver Service: A Retrospective Evaluation

  2023cites this paper
• Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies

  2023cites this paper
• Diagnostic Performance of Abbreviated MRI for HCC Detection in Patients with Non-alcoholic Fatty Liver Disease.

  2023cites this paper
• NCOA5 Haploinsufficiency in Myeloid-Lineage Cells Sufficiently Causes Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma

  2023cites this paper
• The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products

  2022cites this paper
• Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals

  2022cites this paper
• Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet–Fed Mice

  2022cites this paper
• World Journal of Gastroenterology Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental

  2022cites this paper
• Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?

  2022cites this paper
• Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge

  2021cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper
• World Journal of Gastroenterology

  year unknowncites this paper